PT-141 is the research name for bremelanotide, a peptide that acts on melanocortin receptors in the brain rather than on blood flow. Compounded PT-141 at Telos Rx is prescribed only after review by a licensed provider.
If searching "what is PT-141" left you with a mix of forum threads and product pages, this is the plain-English version: the molecule, the receptor pathway, the trials, the difference between the FDA-approved brand and compounded preparations, and what a provider review involves.
PT-141, Bremelanotide and Vyleesi: One Molecule, Three Names
Search results treat these as separate subjects. They are not. PT-141 is the development code, bremelanotide is the generic drug name, and Vyleesi is the FDA-approved brand. Anything written about the PT-141 peptide is describing bremelanotide.
That is why "peptide PT-141", "peptides PT-141" and "PT141 peptide" all return the same compound: a short synthetic peptide given by injection rather than swallowed.
Bremelanotide sits in the melanocortin peptide family, the same research lineage that produced the melanotan compounds. It is not a tanning product and is not used as one. That shared chemistry is, however, why pigment changes show up in the safety data later on this page.
How PT-141 Works: The Melanocortin Pathway
Bremelanotide is a melanocortin receptor agonist. It binds MC3R and MC4R receptors concentrated in the hypothalamus, the part of the brain that coordinates drive, motivation and arousal signalling.
This is a central mechanism, not a circulatory one. PT-141 does not widen blood vessels and does not act on the tissue involved in an erection. It acts earlier in the chain, on the brain signalling that comes before physical arousal.
One practical consequence follows from that. Because the activity is central, a response does not strictly depend on sexual stimulation already being present. Drugs that work through the vascular pathway do depend on it.
Central Versus Peripheral: The Comparison That Matters
The treatments most people already know are PDE5 inhibitors, the class that includes sildenafil and tadalafil. They block an enzyme in vascular smooth muscle, increasing blood flow once arousal is underway.
| PT-141 (bremelanotide) | PDE5 inhibitors | |
|---|---|---|
| Drug class | Melanocortin receptor agonist (peptide) | Enzyme inhibitor (small molecule) |
| Where it acts | Central nervous system, MC3R and MC4R in the hypothalamus | Peripheral, vascular smooth muscle |
| What it targets | Desire and arousal signalling | Blood flow to erectile tissue |
| Needs sexual stimulation first | Not strictly required by the mechanism | Yes |
| Route studied | Subcutaneous injection, as needed | Oral tablet |
| FDA-approved population | Premenopausal women with acquired, generalized HSDD (as Vyleesi) | Erectile dysfunction in men |
Neither approach makes the other redundant, because they act at different points in the same sequence. The full side-by-side is in PT-141 vs Viagra and Cialis.
If the central mechanism sounds closer to what you are actually dealing with than a blood-flow drug, the next step is a written intake reviewed by a licensed provider.
See PT-141 at Telos RxWho the Research Actually Studied
The phase 3 evidence base is the RECONNECT program, two randomized, double-blind, placebo-controlled trials in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). "Acquired" means desire was present and then declined. "Generalized" means the decline was not limited to one situation or one partner.
The published phase 3 results used co-primary endpoints covering sexual desire and the distress associated with low desire, both measured with validated questionnaires. A peer-reviewed review of the same data walks through the receptor pharmacology and tolerability in more detail.
On the strength of that program, the FDA approved Vyleesi in 2019. Acquired, generalized HSDD in premenopausal women remains the only FDA-approved indication for bremelanotide. Postmenopausal women and men were not part of the approved population.
Research in men exists but sits outside that approval. Phase 2 work in men with erectile dysfunction reported a dose-dependent erectile response, with effects described in roughly the 30 to 60 minute range. Any use in men is off-label. The population-specific detail is in PT-141 for men and PT-141 for women.
Vyleesi and Compounded PT-141 Are Not the Same Product
This is the distinction most articles blur, and it matters both clinically and legally.
- Vyleesi is an FDA-approved 1.75 mg subcutaneous autoinjector. Its label specifies administration about 45 minutes before anticipated sexual activity, no more than one dose in 24 hours, and no more than eight doses in a month.
- Compounded PT-141 is not FDA-approved. It is prepared by licensed US compounding pharmacies under federal compounding regulations, against a prescription written for an individual patient.
- Compounded preparations are not required to mirror the brand's concentration or presentation, and what is available can differ from state to state.
- Both require a prescription. Neither is a supplement, and neither should be sourced outside a licensed pharmacy.
Reported clinical parameters are collected in PT-141 dosage: what clinical research shows. Those figures describe trial and label conditions. They are not instructions, and the prescribing provider decides what is appropriate for any individual.
Why Injection Rather Than Nasal Spray
An intranasal bremelanotide formulation was studied earlier in development. It was not carried forward to FDA approval, because of blood pressure findings associated with that route.
The subcutaneous route is the one that went through to approval, and it is the form relevant to compounded prescribing today. The comparison is set out in PT-141 nasal spray vs injection.
What the Trials Reported on Safety
Nausea was the most commonly reported adverse effect, in roughly 40 percent of participants, and it was usually transient. Flushing, headache and injection-site reactions were also reported. Longer-term open-label follow-up reported no new safety signals.
Trials also recorded transient increases in blood pressure alongside a modest decrease in heart rate. Focal hyperpigmentation, meaning small darkened patches of skin, has been reported with repeated dosing.
People with uncontrolled hypertension or known cardiovascular disease were excluded from the trials, and bremelanotide is not for them. The fuller account is in PT-141 side effects: what trials reported.
What a Provider Evaluation Involves
Telos Rx is an online-first, asynchronous telehealth service. You complete a written intake covering health history, current medications, blood pressure history and what you are hoping to address. A licensed provider reviews it and responds in writing, without a scheduled appointment.
Everything is subject to medical approval by a licensed provider, and approval is not guaranteed. If PT-141 is not suitable, the provider says so and may suggest a different direction. Compounded PT-141 through Telos Rx is an as-needed subcutaneous dose taken ahead of anticipated intimacy, available in all 50 states, with formulations that may vary by state.
Keep Reading: The Rest of This Guide
- PT-141 Dosage: What Clinical Research Shows
- PT-141 Side Effects: What Trials Reported
- PT-141 for Women: HSDD, Vyleesi and Research
- PT-141 for Men: What the Research Shows
- PT-141 Nasal Spray vs Injection: Compared
- PT-141 vs Viagra and Cialis: How They Differ
- 5 Research-Backed Benefits of PT-141
- PT-141 vs Kisspeptin
- Peptides for Libido: PT-141 and Kisspeptin Research
Frequently Asked Questions
What is PT-141 used for?
Bremelanotide is FDA-approved, under the brand Vyleesi, for acquired and generalized hypoactive sexual desire disorder in premenopausal women. That is the only approved use. Compounded PT-141 is prescribed off-label in other contexts, including in men, where the supporting evidence is earlier-phase. A licensed provider decides whether it is appropriate.
Is PT-141 the same as Vyleesi?
The active molecule is the same. PT-141 was the research code, bremelanotide is the drug name, and Vyleesi is the FDA-approved 1.75 mg subcutaneous autoinjector. Compounded PT-141 contains the same active peptide but is not FDA-approved, and its concentration and presentation can differ from the brand product.
Is PT-141 a hormone or a steroid?
Neither. PT-141 is a short synthetic peptide that acts as an agonist at melanocortin receptors, mainly MC3R and MC4R. It is not testosterone, not an anabolic steroid, and not a hormone replacement. It is also chemically related to the melanotan research peptides, but it is not a tanning agent.
Can men take PT-141?
Use in men is off-label, because the FDA approval covers premenopausal women with HSDD only. Phase 2 research in men with erectile dysfunction reported a dose-dependent erectile response, with effects described in roughly the 30 to 60 minute range. Whether it is suitable is a decision for a licensed provider after reviewing health history.
Is compounded PT-141 legal in the US?
Compounded medications can be legally prepared by licensed US compounding pharmacies under federal compounding regulations, against a valid prescription for an individual patient. They are not FDA-approved, which means they have not been through the agency's own review of safety and effectiveness. Provider oversight is required.
Who should not use bremelanotide?
People with uncontrolled hypertension or established cardiovascular disease were excluded from the clinical trials, and bremelanotide is not intended for them. Blood pressure history, current medications and other conditions are all part of the review. Approval is subject to evaluation by a licensed provider and is never guaranteed.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Ready to find out whether PT-141 is a reasonable fit for you? Start with the PT-141 product page, then complete the written intake for your evaluation: start an online visit for men or start an online visit for women. A licensed provider reviews every request, and approval is not guaranteed.